Ask AI
ProCE Banner Series

Unlocking the Full Potential of HER2-Directed ADCs in HER2-Mutant and Overexpressing Lung Cancer: Testing Applications, Data Insights, and Effective Decision-making for Patient-Centric Care

This 1-hour interactive live discussion will provide expert perspectives on the role of HER2 in oncogenic pathway signaling, incidence of HER2 mutations and overexpression in NSCLC, optimal methods for assessing HER2 alterations, key efficacy and safety data on HER2-directed ADCs in HER2-mutant and HER2-overexpressing NSCLC, treatment guideline recommendations, and approaches to manage treatment-emergent adverse events.

  AAPA
  | ACPE
  | AMA
  | ANCC
Who Should Attend

This activity is designed to address the educational needs of oncologists, advanced practice providers, pharmacists, physician associates, nurses, and other healthcare professionals who care for patients with NSCLC. 

All Events

Unlocking the Full Potential of HER2-Directed ADCs in HER2-Mutant and Overexpressing Lung Cancer: Testing Applications, Data Insights, and Effective Decision-making for Patient-Centric Care

Upcoming Events

December

16

2025

12:00 PM - 1:00 PM Eastern Time (ET)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge, confidence, and competence to optimize the integration of HER2-directed ADC therapy into clinical practice for patients with NSCLC.

Target Audience
This activity is designed to address the educational needs of oncologists, advanced practice providers, pharmacists, physician associates, nurses, and other healthcare professionals who care for patients with NSCLC. 

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Apply guideline-recommended testing and assessment for patients with NSCLC to identify patients with HER2 alterations who may benefit from HER2-directed ADC therapy

  • Integrate the latest clinical data and guidelines for treating HER2-mutant and overexpressing NSCLC, including emerging data for the use of HER2-directed ADCs in earlier lines of therapy

  • Implement personalized care plans for patients with NSCLC, including the use of reduced dosing regimens to mitigate and manage treatment-related adverse events in patients receiving HER2-directed ADC therapy

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.0 contact hour.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-25-451-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

CME Passport

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC

Supporters

Supported by educational grants from AstraZeneca and Daiichi Sankyo, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191